Literature DB >> 20233513

Procalcitonin: a novel cardiac marker with prognostic value in acute coronary syndrome.

H E Ataoğlu1, F Yilmaz, I Uzunhasan, F Cetin, Lü Temiz, Y E Döventaş, A Kaya, M Yenigün.   

Abstract

Procalcitonin (PCT) is implicated as an inflammatory marker in early atherosclerosis. In order to investigate the clinical consequences of increased PCT levels in acute coronary syndrome (ACS), 77 patients (29 with non-ST-elevation myocardial infarction [MI], 34 with ST-elevation MI and 14 with unstable angina pectoris) were included and followed up for 6 months. The PCT levels were determined at initial presentation and within 48 h of admission. Five patients died during hospitalization and their PCT levels within 48 h of admission were significantly higher than survivors (n = 72) (0.588 +/- 0.56 versus 0.399 +/- 1.33 ng/ml, respectively). The PCT levels within 48 h post-admission in the nine patients who died within 6 months were also significantly higher compared with the survivors (0.451 +/- 0.44 versus 0.406 +/- 1.37 ng/ml, respectively). It is concluded that higher PCT levels within 48 h post-admission may reflect an inflammatory state that is associated with increased early and 6-month mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233513     DOI: 10.1177/147323001003800106

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  9 in total

1.  Procalcitonin and Pentraxin-3: Current biomarkers in inflammation in white coat hypertension.

Authors:  H Yavuzer; M Cengiz; S Yavuzer; M Rıza Altıparmak; B Korkmazer; H Balci; A L Yaldıran; H Uzun
Journal:  J Hum Hypertens       Date:  2015-06-04       Impact factor: 3.012

2.  Serum hsCRP and procalcitonin levels in dyspeptic patients infected with CagA-positive Helicobacter pylori.

Authors:  Bulur Oktay; Yeniova Abdullah Ozgur; Kucukazman Metin; Ata Naim; Asilturk Zeliha; Yıldız Mehmet; Kefeli Ayse; Basyigit Sebahat; Aktas Bora; Nazlıgul Yasar
Journal:  J Clin Lab Anal       Date:  2014-08-17       Impact factor: 2.352

Review 3.  Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable angina.

Authors:  George Tsaknis; Iraklis Tsangaris; Ignatios Ikonomidis; Argirios Tsantes
Journal:  Dis Markers       Date:  2014-06-19       Impact factor: 3.434

4.  Evaluation of the Septifast MGrade Test on Standard Care Wards--A Cohort Study.

Authors:  Franz Ratzinger; Irene Tsirkinidou; Helmuth Haslacher; Thomas Perkmann; Klaus G Schmetterer; Dieter Mitteregger; Athanasios Makristathis; Heinz Burgmann
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

5.  Do MCHC, MPV, and Procalcitonin Levels Determine Prognosis in Acute Coronary Syndrome?

Authors:  Serhat Karaman; Abuzer Coskun
Journal:  Emerg Med Int       Date:  2019-07-18       Impact factor: 1.112

Review 6.  Post-Myocardial Infarction Ventricular Remodeling Biomarkers-The Key Link between Pathophysiology and Clinic.

Authors:  Maria-Madălina Bostan; Cristian Stătescu; Larisa Anghel; Ionela-Lăcrămioara Șerban; Elena Cojocaru; Radu Sascău
Journal:  Biomolecules       Date:  2020-11-23

7.  Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome.

Authors:  Rita Pavasini; Gioele Fabbri; Federico Marchini; Nicola Bianchi; Maria Angela Deserio; Federico Sanguettoli; Filippo Maria Verardi; Daniela Segala; Graziella Pompei; Elisabetta Tonet; Matteo Serenelli; Serena Caglioni; Gabriele Guardigli; Gianluca Campo; Rosario Cultrera
Journal:  J Clin Med       Date:  2022-01-22       Impact factor: 4.241

8.  Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management.

Authors:  Antoine Kossaify; Annie Garcia; Sami Succar; Antoine Ibrahim; Nicolas Moussallem; Mikhael Kossaify; Gilles Grollier
Journal:  Biomark Insights       Date:  2013-09-03

Review 9.  Emerging families of biomarkers for coronary artery disease: inflammatory mediators.

Authors:  Josef Yayan
Journal:  Vasc Health Risk Manag       Date:  2013-07-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.